Ruti Aga's Six Years: Two for the Drug, Four for the Prescription

The Athletics Integrity Unit's statement carries no mark, no split, no field strength. What it carries is a division. Ruti Aga's six-year ban is cut into two unequal accounts: two years for the presence of methylprednisolone, four years for the piece of paper manufactured to justify it. The drug belongs to the athlete's body. The paper belongs to the people standing around her. When four of six years go to the paperwork, the investigation has already climbed off the body and into the filing cabinet.

The case opens at a half marathon in China in March, which Aga won, and at which the sample she gave came back positive. The winning time, the splits, the depth of the field — none of it appears in the statement. What appears instead is a knee injury, a family member described as a doctor, a clinic that did not exist, and a prescription that the clinic itself disowned.

Aga is 32, Ethiopian, the 2026 Tokyo Marathon winner, with three second places at World Marathon Majors on her record. External records put her best in the region of 2:18 — second in Berlin 2026, first in Tokyo 2026. That is the profile I file under low-race-count, high-appearance-fee: a 2:18–2:20 marathoner who races the Majors selectively and fills the gaps with Asian label races, where the start money is real and the scrutiny has historically felt thinner. The March half marathon in China sits precisely in that gap.

The gap is now the most heavily watched piece of real estate in the sport. When the national camp shut in 2026 and the April Federation Cup was called off, I spent that hiatus on the phone to Railways, Services and state police clerks, mapping whose salary kept running through the lockdown and whose quietly stopped. The exercise settled one thing for good: the real question always comes to rest on the lowest document in the system. Every shutdown invents a quota economy, and every quota economy hides a queue. Here, the lowest document is a medical prescription.

The statement dates the provisional suspension from 10 September, and Thursday's decision backdated the ban to the same day. Count six years forward from 10 September and the door to a comeback opens at 38.

A technical correction is unavoidable here, because nearly every report on this case has filed the substance under the wrong heading. Methylprednisolone has been described as a prohibited steroid. On the WADA Prohibited List it is a glucocorticoid, class S9, and it is prohibited in-competition only, by injection, oral or rectal route. Keeping it away from the class S1 anabolic steroids matters because the two build legal consequences differently. An S9 case is decided by timing and route, not by an intent to build muscle.

Which means Aga had a legitimate defence available. Intra-articular methylprednisolone for knee synovitis is ordinary sports-medicine practice in distance runners. With real records, correct dates and the route documented, the argument could have been made that the injection went in well before competition and that no residue should have survived to the sample. That argument collapsed the moment a manufactured document was put forward in place of a real one. In a case where the defence was open, forging the paperwork means burning your strongest argument with your own hands.

Now the ledger. Two years for the presence violation, four for tampering. The addition matches the standard architecture of the Code: where intent is not proven for a Specified Substance, presence sits at two years, and the standard tampering sanction is four. The real message in the arithmetic is that the panel rejected the no-significant-fault mitigation. Had it accepted that the athlete took the drug without serious negligence, the presence sanction could have come down. It did not come down.

The third element gets the least discussion: backdating to 10 September. Read it as procedure, not relief. Time served under provisional suspension counts against the ban, so the clock was already running and the athlete gained nothing in real terms.

The tampering investigation failed three separate verification checks, and that is the most instructive part of the file. First, the physician named on the prescription was unregistered; he was a family member. Second, the clinic named on the prescription did not exist. Third, the explanation about an old prescription pad from a former workplace was rejected by that clinic itself. Not one of the three checks passed — which is not a filing error but evidence of an empty chair where a credentialed team physician should have been sitting.

The statement does not say what happened to the March result or its prize money. Standard practice disqualifies the competition at which the sample was collected, and ranking points accrued after that date go with it. The winner's certificate has been entered into the same ledger as the ban. What survives is the 2026 Tokyo title and the three Major silvers, because the violation attaches to a later race and earlier results are not automatically annulled.

At Tokyo 2026 I spent two days in the mixed zone with the men's 4x400 squad, whose national record 3:00.25 in the heats still left them outside the final. The lesson there was that the distance between a statement and a reality is usually measured by a single document — somebody's time, somebody's split, somebody's name. At Kalinga I count strides before I count medals; watching frames off a borrowed 70-200mm lens at the 2026 Asian Championships taught me that technical detail does not lie. Here the technical detail is a prescription date, an injection route and a sample time. The dead-ball ledger never lies; live play just distracts — and in this case the live coverage could not even get the drug's class right.

The uncomfortable question is why six years attached to a substance with no proven endurance benefit. Methylprednisolone reduces pain and swelling; it does not build muscle. That does not make the sanction wrong — the four tampering years stand on their own. It does mean that every report reading this as a steroid bust has missed the actual lesson and has distorted the comparison with anabolic cases before the comparison was even made.

The actual lesson is that the enforcement frontier has moved off detection and onto document verification. The old question was whether a substance turned up in the body. The new question is whether the explanation offered can be verified. The day the needle swings to documents, the athletes carrying the most risk are the ones racing without a credentialed medical team — and several East African road-racing clusters are in exactly that condition. That is a count, not a complaint about administrators. Knee pain in those clusters is routinely treated through informal networks, because an athlete living off start money between Majors and label races has no permanent medical structure to fall back on.

The second page of the same ledger is the Chinese label circuit. Large start money, deep East African elite fields, and the AIU's highest-yield testing. The appearance-fee economy and the testing economy are now colliding inside the same race. The fixture that was a safe income tier yesterday is the most densely policed zone today.

Run the counterfactual as well. With genuine medical records and a documented route and timing, the presence charge could have been fought at the no-fault end, and the tampering charge would never have existed. In the best case, a TUE-consistent treatment plan and correct washout timing produce no case at all. The appeal window is open — typically around twenty-one days from the reasoned decision — but a document-based forgery finding is hard to overturn.

On the competitive landscape the effect is nil. Ethiopian women's marathon depth is such that a 2:18 performer is not automatically selectable; the removal of one athlete leaves no measurable hole in national-team capacity. Aga's three Major silvers were commercial-tier results, not championship conversions. What changes is not the medal table. It is the paperwork era.

The next question is not whether Aga appeals. It is how many athletes in the same training clusters are racing on prescriptions that were never verified — and when the AIU next reaches an old prescription pad, how many chairs in that clinic will turn out to be empty, and whose account the empty chairs will be charged to.